Roberto Santambrogio1, Jason Chiang2, Matteo Barabino3, Franca Maria Meloni4,5, Emanuela Bertolini6, Fabio Melchiorre7, Enrico Opocher3. 1. UOC di Chirurgia Epato-bilio-pancreatica e Digestiva, Ospedale San Paolo, Università di Milano, Milan, Italy. rsantambrogio@mclink.it. 2. Department of Radiology, University of Wisconsin, Madison, WI, USA. 3. UOC di Chirurgia Epato-bilio-pancreatica e Digestiva, Ospedale San Paolo, Università di Milano, Milan, Italy. 4. Servizio di Radiologia Ecografia Interventistica, Ospedale Valduce, Como, Italy. 5. Servizio di radiologia Interventistica e di Procedure Speciali, Casa di Cura Igea, Milan, Italy. 6. Divisione di Medicina Interna-Epatologia, San Paolo Hospital, University of Milan School of Medicine, Milan, Italy. 7. Servizio di Radiologia Diagnostica ed Interventistica, Ospedale San Paolo, Università di Milano, Milan, Italy.
Abstract
BACKGROUND: Laparoscopic thermal ablation is a common alternative to surgical resection in treating hepatic tumors, particularly in those located in difficult-to-reach locations. OBJECTIVE: The aim of this study was to compare the safety and long-term efficacy of laparoscopic radiofrequency ablation (RFA) and microwave ablation (MWA) in treating hepatocellular carcinoma (HCC). METHOD: From February 2009 to May 2015, data from patients with HCC nodules who had undergone either laparoscopic MWA or laparoscopic RFA were examined. Complications, complete ablation rates, local tumor progression (LTP) rates, and disease-free and cumulative survival rates were compared between the two treatment groups. RESULTS: A total of 154 patients with HCC (60 MWA and 94 RFA) were treated via the laparoscopic approach. Major complication rates were identified as 1 and 2 % in the RFA and MWA groups, respectively (p = 0.747). Complete ablation rates were 95 % for both treatment groups (p = 0.931), and LTP rates were 21.2 % for RFA and 8.3 % for MWA (p = 0.034). Disease-free survival rates at 5 years were 19 % in the RFA group and 12 % in the MWA group (p = 0.434), while cumulative survival rates at 5 years were 50 % in the RFA group and 37 % in the MWA group (p = 0.185). CONCLUSION: Laparoscopic RFA and MWA appear to be safe in the treatment of early-stage HCC. The LTP rates were lower in the laparoscopic MWA group compared with the laparoscopic RFA group, but their respective overall and disease-free survival rates remained similar.
BACKGROUND: Laparoscopic thermal ablation is a common alternative to surgical resection in treating hepatic tumors, particularly in those located in difficult-to-reach locations. OBJECTIVE: The aim of this study was to compare the safety and long-term efficacy of laparoscopic radiofrequency ablation (RFA) and microwave ablation (MWA) in treating hepatocellular carcinoma (HCC). METHOD: From February 2009 to May 2015, data from patients with HCC nodules who had undergone either laparoscopic MWA or laparoscopic RFA were examined. Complications, complete ablation rates, local tumor progression (LTP) rates, and disease-free and cumulative survival rates were compared between the two treatment groups. RESULTS: A total of 154 patients with HCC (60 MWA and 94 RFA) were treated via the laparoscopic approach. Major complication rates were identified as 1 and 2 % in the RFA and MWA groups, respectively (p = 0.747). Complete ablation rates were 95 % for both treatment groups (p = 0.931), and LTP rates were 21.2 % for RFA and 8.3 % for MWA (p = 0.034). Disease-free survival rates at 5 years were 19 % in the RFA group and 12 % in the MWA group (p = 0.434), while cumulative survival rates at 5 years were 50 % in the RFA group and 37 % in the MWA group (p = 0.185). CONCLUSION: Laparoscopic RFA and MWA appear to be safe in the treatment of early-stage HCC. The LTP rates were lower in the laparoscopic MWA group compared with the laparoscopic RFA group, but their respective overall and disease-free survival rates remained similar.
Authors: Riccardo Lencioni; Thierry de Baere; Robert C Martin; Charles W Nutting; Govindarajan Narayanan Journal: Liver Cancer Date: 2015-10-21 Impact factor: 11.740
Authors: Sebastian Stintzing; Jobst von Einem; Christoph Fueweger; Alfred Haidenberger; Michael Fedorov; Alexander Muavcevic Journal: Cancer Res Treat Date: 2018-04-16 Impact factor: 4.679
Authors: Mrudula B Glassberg; Sudip Ghosh; Jeffrey W Clymer; Rana A Qadeer; Nicole C Ferko; Behnam Sadeghirad; George Wj Wright; Joseph F Amaral Journal: Onco Targets Ther Date: 2019-08-13 Impact factor: 4.147